Chemical biologist Eric Wang joins Sanford Burnham Prebys

Eric Wang, Ph.D., has joined our NCI-designated Cancer Center an assistant professor in the Tumor Initiation and Maintenance Program. His lab will focus on using and developing chemical tools to influence the activity of tumor and immune cells.

Endeavor Biomedicines licenses ULK1/2 inhibitor from Sanford Burnham Prebys and the Salk Institute

The exclusive agreement with Endeavor Biomedicines is for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1/2, a protein involved in cell recycling.

Researchers identify a novel player in acute myeloid leukemia

RNF5 is required for AML growth. The protein could be inhibited or used as a biomarker to improve patient outcomes.

Sanford Burnham Prebys drug enters Phase 1 study for the treatment of tobacco use disorder

A drug discovered in the lab of Nicholas Cosford, Ph.D., professor and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys, has entered a Phase 1 clinical study.